ONCAlert | Upfront Therapy for mRCC

Bladder Cancer VIEW MORE >>

Pembrolizumab is now FDA approved for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.